Related Experiment Video
Updated: May 12, 2026
14:39
Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
Published on: November 4, 2010
Clinical asthma phenotypes and therapeutic responses
1Allergy, Clinical Immunology and Respiratory Medicine Unit, Faculty of Medicine, Mansoura University, P.O. 35516 Box 50, Mansoura, Egypt.
ISRN Pediatrics
|April 23, 2013
Summary
Asthma treatment varies by patient symptoms. Children with shortness of breath responded to fluticasone, while cough symptoms indicated montelukast effectiveness, guiding personalized asthma medication choices.
Area of Science:
- Pediatric Pulmonology
- Clinical Immunology
- Pharmacogenomics
Background:
- Asthma is a complex respiratory condition with diverse patient responses to standard treatments.
- Understanding asthma heterogeneity is crucial for optimizing therapeutic strategies.
- Current treatment guidelines may not fully account for symptom-based variations in asthma management.
Purpose of the Study:
- To investigate the correlation between asthma phenotypes (shortness of breath, cough, wheeze) and airway inflammatory biomarkers.
- To determine if distinct clinical phenotypes impact treatment response to montelukast and fluticasone propionate.
- To identify patient characteristics that can guide the selection of asthma medications.
Main Methods:
- A randomized controlled trial involving 203 asthmatic children treated with either montelukast or fluticasone propionate for 8 weeks.
- Assessment of serum biomarkers including IL-2Rs, ICAM-1, VCAM-1, total IgE, eosinophil percentage, and eosinophil cationic protein (ECP).
- Measurement of forced expiratory volume in 1 second (FEV1) before and after treatment.
Main Results:
- Children with shortness of breath (SOB) exhibited higher total IgE, older age, and longer disease duration, responding favorably to fluticasone propionate alone.
- The cough phenotype was associated with elevated eosinophilic percentage and sECP, younger age, and shorter disease duration, showing a preference for montelukast.
- The wheezy phenotype displayed a mixed response, indicating potential benefit from both inhaled corticosteroids (ICS) and leukotriene receptor antagonists (LTRAs).
Conclusions:
- Distinct asthma phenotypes correlate with specific inflammatory profiles and differential responses to inhaled corticosteroids (ICS) and leukotriene receptor antagonists (LTRAs).
- Clinical characteristics such as predominant symptom (SOB vs. cough) can guide the choice between fluticasone propionate and montelukast in pediatric asthma.
- Personalized asthma management strategies based on phenotype-driven biomarker analysis can improve treatment efficacy.
More Related Videos
Related Concept Videos
01:20Asthma: Pathogenesis and Management
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
01:26Asthma-II: Pathophysiology and Classification
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
01:13Asthma III: Clinical Manifestations
Asthma presents with a characteristic pattern of episodic respiratory symptoms that reflect underlying airway inflammation, bronchoconstriction, and mucus hypersecretion. Although severity varies among individuals, certain clinical manifestations are considered hallmarks of the disorder and often guide diagnosis and assessment.Respiratory SymptomsA persistent cough is one of the most common early features of asthma. It is frequently dry and tends to worsen at night or in the early morning,...
01:30Asthma-IV: Diagnostic and Management
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
01:28Asthma I: Introduction
Asthma is a chronic inflammatory disorder of the airways characterized by variable airflow obstruction and heightened bronchial responsiveness to a wide range of triggers. The underlying inflammation leads to airway swelling, mucus hypersecretion, and smooth muscle constriction, all of which narrow the airway lumen and impede airflow. Clinically, asthma presents with recurrent episodes of wheezing, shortness of breath, chest tightness, and coughing, symptoms that typically vary in intensity and...
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...